tiprankstipranks
Craneware Plc (GB:CRW)
:CRW

Craneware (CRW) AI Stock Analysis

Compare
12 Followers

Top Page

GBCraneware
(LSE:CRW)
61Neutral
Craneware's strong financial performance is a key strength, demonstrating robust revenue and profit growth. However, the stock is currently facing bearish technical signals, with prices below major moving averages and low momentum indicators. Additionally, the high P/E ratio suggests potential overvaluation. These factors combined result in a moderate overall stock score.

Craneware (CRW) vs. S&P 500 (SPY)

Craneware Business Overview & Revenue Model

Company DescriptionCraneware (CRW) is a leading provider of financial performance optimization solutions within the healthcare sector. The company specializes in revenue integrity and data analytics software that helps hospitals and healthcare organizations enhance their financial outcomes. By leveraging its suite of products, Craneware enables healthcare institutions to manage their billing, compliance, and revenue cycles more effectively.
How the Company Makes MoneyCraneware makes money primarily through the sale and licensing of its software solutions to healthcare providers. The company's revenue model is based on subscription fees, where clients pay recurring fees for access to its cloud-based software platforms. Craneware also offers various consulting and professional services to support the implementation and optimization of its solutions, which constitute another revenue stream. Additionally, Craneware collaborates with key industry partners to expand its market reach and enhance the functionality of its products, further contributing to its earnings.

Craneware Financial Statement Overview

Summary
Craneware exhibits strong financial performance with robust revenue and profit growth, efficient operations, and a stable balance sheet. The company maintains strong cash flow generation, although there is room for improvement in net profit margins and free cash flow growth.
Income Statement
85
Very Positive
Craneware demonstrated strong revenue growth of 8.77% from 2023 to 2024, with a solid gross profit margin of 85.7% and a net profit margin of 6.2% in 2024. The EBIT margin was 10.4%, indicating efficient operations, while the EBITDA margin of 28.7% reflects healthy cash generation from operations. Overall, the company shows robust profitability and growth, although net profit margins could be improved.
Balance Sheet
80
Positive
The debt-to-equity ratio improved significantly, reflecting a strong balance sheet with a lower debt burden. Return on equity is moderate at 3.6%, indicating room for improvement in asset utilization. The equity ratio is a healthy 60.4%, suggesting financial stability. The balance sheet shows prudent financial management with a focus on maintaining low leverage.
Cash Flow
78
Positive
Free cash flow decreased from 2023 to 2024, but the company maintains a solid operating cash flow to net income ratio of 3.6, highlighting efficient cash generation relative to earnings. The free cash flow to net income ratio is favorable, showing a strong conversion of earnings into cash. The company should focus on improving free cash flow growth to enhance financial flexibility.
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
189.27M174.02M165.54M75.58M71.49M
Gross Profit
162.20M148.44M142.37M70.20M66.97M
EBIT
19.73M19.23M18.13M13.24M19.21M
EBITDA
54.26M51.60M47.54M18.48M24.06M
Net Income Common Stockholders
11.70M9.23M9.41M12.90M16.84M
Balance SheetCash, Cash Equivalents and Short-Term Investments
34.59M78.54M47.16M235.62M47.85M
Total Assets
543.65M576.98M568.79M311.60M115.76M
Total Debt
40.15M86.69M113.08M1.15M2.02M
Net Debt
5.56M8.15M65.93M-234.47M-45.83M
Total Liabilities
215.06M249.13M235.77M51.32M47.36M
Stockholders Equity
328.59M327.84M333.02M260.28M68.39M
Cash FlowFree Cash Flow
24.91M83.20M12.93M13.21M10.96M
Operating Cash Flow
41.86M98.75M26.96M23.54M20.67M
Investing Cash Flow
-15.81M-15.34M-307.32M-10.32M-9.71M
Financing Cash Flow
-70.00M-53.28M91.90M174.55M-10.72M

Craneware Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1860.00
Price Trends
50DMA
2015.90
Negative
100DMA
2073.05
Negative
200DMA
2170.97
Negative
Market Momentum
MACD
-40.99
Positive
RSI
38.72
Neutral
STOCH
9.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Negative. The current price of 1860 is below the 20-day moving average (MA) of 1932.00, below the 50-day MA of 2015.90, and below the 200-day MA of 2170.97, indicating a bearish trend. The MACD of -40.99 indicates Positive momentum. The RSI at 38.72 is Neutral, neither overbought nor oversold. The STOCH value of 9.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRW.

Craneware Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
£107.90M219.140.72%0.68%-1.22%-92.99%
GBCRW
61
Neutral
£640.83M68.823.56%1.57%3.99%22.16%
GBFDP
52
Neutral
£348.64M-27.75%-22.83%-350.82%
49
Neutral
$7.05B0.34-55.09%2.46%25.27%-3.43%
GBSYN
40
Underperform
£4.52M-28.11%-54.20%75.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:CRW
Craneware
1,850.00
-213.61
-10.35%
GB:SYN
Oilex Ltd
0.03
-0.07
-70.00%
GB:FDP
FD Technologies
1,578.00
466.00
41.91%
GB:TRCS
Tracsis
357.00
-559.11
-61.03%

Craneware Corporate Events

Business Operations and Strategy
Craneware Announces Change in Major Shareholder Holdings
Neutral
Feb 19, 2025

Craneware plc has announced a change in its major holdings as Aegon Ltd has acquired voting rights totaling 5.168% of Craneware’s shares. This acquisition indicates a strategic move by Aegon, potentially impacting Craneware’s shareholder dynamics and signaling confidence in the company’s market positioning.

Craneware Reports Strong H1 FY25 Growth and Announces New Director
Jan 13, 2025

Craneware plc announced a positive trading update for the first half of the fiscal year 2025, with revenues surpassing $100 million and adjusted EBITDA reaching approximately $30.3 million, driven by the success of its Trisus platform and strategic partnerships. The company also appointed Susan Nelson as a Non-Executive Director, bringing extensive experience in healthcare finance, and anticipates a stable demand environment in the US healthcare market, supported by strong cash reserves and reduced debt.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.